Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lewis J. Fermaglich
Observed names:
Fermaglich, Lewis J.,
Lewis Fermaglich
Institution:
United States Food and Drug Administration
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Captain James A. Lovell Federal Health Care Center
ORCID:
0000-0001-7151-1615
Observed ORCID:
0000-0001-7151-1615
OpenAlex ID:
A5030808295
A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act
2023
·
Lewis J. Fermaglich
, Kathleen L. Miller
·
Orphanet Journal of Rare Diseases
·
173
PDF
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
2021
·
Kathleen L. Miller
, Lewis J. Fermaglich
, et al.
·
Orphanet Journal of Rare Diseases
·
116
PDF
Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies
2021
·
Kathleen L. Miller
, Selma Kraft
, et al.
·
Expert Opinion on Orphan Drugs
·
23
Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
2024
·
Catherine Mease
, Kathleen L. Miller
, et al.
·
Orphanet Journal of Rare Diseases
·
13
PDF
Determining Commonalities in the Experiences of Patients with Rare Diseases: A Qualitative Analysis of US Food and Drug Administration Patient Engagement Sessions
2023
·
Catherine Mease
, Lewis J. Fermaglich
, et al.
·
Patient
·
12
PDF
Salmonella Cervical Lymphadenitis in an Immunocompetent Child Exposed to a Snake at an Educational Exhibit: A Case Report
2012
·
Lewis J. Fermaglich
, John M. Routes
, et al.
·
Infectious Diseases in Clinical Practice
·
6
The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022
2024
·
Abraham Viju Ipe
, Lewis J. Fermaglich
, et al.
·
Expert Opinion on Orphan Drugs
·
4
Trends in drug development for amyotrophic lateral sclerosis
2023
·
Selma Kraft
, Catherine Mease
, et al.
·
Nature Reviews Drug Discovery
·
4
Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint Studies
2018
·
Lewis J. Fermaglich
, Ru Chen
, et al.
·
Therapeutic Innovation & Regulatory Science
·
2
Correction to: Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
2024
·
Catherine Mease
, Kathleen L. Miller
, et al.
·
Orphanet Journal of Rare Diseases
PDF
Show more works
View as search
Works count:
13
Citation count:
353
H-index:
6
I10-index:
5
Year
Topic
Type